EPIGENETIC ALTERATIONS DRIVING ONCOGENESIS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
DOI:
https://doi.org/10.15407/exp-oncology.2023.03.393Abstract
To the Editor,
Head and neck squamous cell carcinoma (HN- SCC) accounts for about 600,000 new cases globally every year and stands the sixth most common cancer, arising from the squamous epithelium. It is localized in the head and neck area involving oral cavity, pharynx, and larynx. Despite the rigorous therapy, the 5-year overall survival remains poor in HNSCC and has not changed appreciably in the last 30 years. The majority of patients develop resistance to chemotherapeutic agents, and cancer progression occurs. Cetuximab, which targets the epidermal growth factor receptor, and pembrolizumab, an anti-programmed-death ligand 1 antibody, are among few FDA-approved medications. Current therapies are poor and cause severe long-term toxicity, which has a long-term impact on the quality of life [1].......
References
Bhushan B. Head and Neck Cancer: A Comprehensive Review of Head and Neck Squamous Cell Carcinoma. 2019. 155 p. ISBN 13: 9781076302557
Castilho RM, Squarize CH, Almeida LO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 2017;18(7):1506. https://doi.org/10.3390/ijms18071506
Lim Y, Sun CX, Tran P, Punyadeera C. Salivary epigenetic biomarkers in head and neck squamous cell carcinomas. Biomark Med. 2016;10(3):301-313. https://doi.org/10.2217/bmm.16.2
Arantes LMRB, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50(6):587–592. https://doi.org/10.1016/j.oraloncology.2014.02.015
Badawi AM. Important Facts about Cancer Prevention. Trafford Publisher, 2012. 192 p. ISBN 13: 9781466953598
Burkitt K, Saloura V. Epigenetic modifiers as novel therapeutic targets and a systematic review of clinical studies investigating epigenetic inhibitors in head and neck cancer. Cancers (Basel). 2021;13(20):5241. https://doi.org/10.3390/cancers13205241
Suchanti S, Stephen BJ, Awasthi S, Awasthi SK, Singh G, Singh A, et al. Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma. Epigenomics. 2022;14(5):279-293. https://doi. org/10.2217/epi-2020-0348
Gama RR, Arantes LMRB, Sorroche BP, et al. Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. Sci Rep. 2021;11(1):16415. https://doi.org/10.1038/ s41598-021-95845-3
Romanowska K, Sobecka A, Rawłuszko-Wieczorek AA, et al. Head and neck squamous cell carcinoma: epigenetic landscape. Diagnostics. 2021;11(1):34. https://doi.org/10.3390/diagnostics11010034
Janiszewska J, Szaumkessel M, Szyfter K. microRNAs are important players in head and neck carcinoma: a review. Crit Rev Oncol Hematol. 2013;88(3):716-728. https://doi.org/10.1016/j.critrevonc.2013.07.012
Galiveti CR, Kuhnell D, Biesiada J, et al. Small extravesicular microRNA in head and neck squamous cell carcinoma and its potential as a liquid biopsy for early detection. Head Neck. 2023;45(1):212-224. https://doi.org/10.1002/hed.27231
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
